About Insmed Incorporated
https://www.insmed.comInsmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
CEO
William H. Lewis
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2011-03-03 | Reverse | 1:10 |
| 2000-07-31 | Reverse | 1:4 |
ETFs Holding This Stock
Summary
Showing Top 3 of 399
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 16
Price Target
Institutional Ownership
JPMORGAN CHASE & CO
Shares:23.05M
Value:$3.77B
DARWIN GLOBAL MANAGEMENT, LTD.
Shares:20.46M
Value:$3.34B
VANGUARD GROUP INC
Shares:19.94M
Value:$3.26B
Summary
Showing Top 3 of 644
About Insmed Incorporated
https://www.insmed.comInsmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $142.34M ▲ | $508.35M ▲ | $-370.02M ▼ | -259.95% ▲ | $-1.75 ▼ | $-344.32M ▼ |
| Q2-2025 | $107.42M ▲ | $392.22M ▲ | $-321.69M ▼ | -299.48% ▼ | $-1.7 ▼ | $-297.13M ▼ |
| Q1-2025 | $92.82M ▼ | $319.69M ▲ | $-256.58M ▼ | -276.42% ▼ | $-1.42 ▼ | $-232.78M ▼ |
| Q4-2024 | $104.44M ▲ | $308.7M ▲ | $-235.55M ▼ | -225.53% ▲ | $-1.32 ▼ | $-211.74M ▼ |
| Q3-2024 | $93.42M | $285.68M | $-220.52M | -236.04% | $-1.27 | $-196.45M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $1.68B ▼ | $2.36B ▼ | $1.42B ▲ | $945.57M ▼ |
| Q2-2025 | $1.86B ▲ | $2.48B ▲ | $1.23B ▼ | $1.25B ▲ |
| Q1-2025 | $1.2B ▼ | $1.8B ▼ | $1.7B ▼ | $99.16M ▼ |
| Q4-2024 | $1.43B ▼ | $2.03B ▼ | $1.74B ▲ | $285.38M ▼ |
| Q3-2024 | $1.47B | $2.05B | $1.57B | $483.42M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-370.02M ▼ | $-219.76M ▼ | $-762.23M ▼ | $33.41M ▼ | $-949.56M ▼ | $-222.18M ▼ |
| Q2-2025 | $-321.69M ▼ | $-205.57M ▲ | $227.84M ▲ | $857.81M ▲ | $881.08M ▲ | $-209.05M ▲ |
| Q1-2025 | $-256.58M ▼ | $-262.09M ▼ | $80.41M ▼ | $29M ▼ | $-151.78M ▼ | $-272.16M ▼ |
| Q4-2024 | $-235.55M ▼ | $-195.98M ▼ | $131.76M ▲ | $159.31M ▼ | $93.58M ▲ | $-202.75M ▼ |
| Q3-2024 | $-220.52M | $-180.92M | $-1B | $397.2M | $-785.35M | $-184.6M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 |
|---|---|---|
 Reportable Segment | $90.00M ▲ | $110.00M ▲ |
Revenue by Geography
| Region | Q4-2024 | Q3-2025 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 Europe And The Rest Of The World | $10.00M ▲ | $0 ▼ | $10.00M ▲ | $10.00M ▲ |
 JAPAN | $50.00M ▲ | $0 ▼ | $20.00M ▲ | $30.00M ▲ |
 NonUS | $0 ▲ | $40.00M ▲ | $0 ▼ | $0 ▲ |
 UNITED STATES | $130.00M ▲ | $100.00M ▼ | $60.00M ▼ | $70.00M ▲ |
CEO
William H. Lewis
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2011-03-03 | Reverse | 1:10 |
| 2000-07-31 | Reverse | 1:4 |
ETFs Holding This Stock
Summary
Showing Top 3 of 399
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 16
Price Target
Institutional Ownership
JPMORGAN CHASE & CO
Shares:23.05M
Value:$3.77B
DARWIN GLOBAL MANAGEMENT, LTD.
Shares:20.46M
Value:$3.34B
VANGUARD GROUP INC
Shares:19.94M
Value:$3.26B
Summary
Showing Top 3 of 644